A new study shows that combining apalutamide with hormone therapy before and after surgery significantly reduces the risk of metastasis and death in high-risk prostate cancer patients.
In a groundbreaking international Phase III clinical trial, researchers have demonstrated that treating high-risk localized or locally advanced prostate cancer patients with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—in conjunction with hormone therapy before and after surgery significantly reduces the risk of metastasis and death. The study was led by Mary-Ellen Taplin, MD, a medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.
The trial involved high-risk prostate cancer patients who were administered apalutamide in addition to standard hormone therapy both before and after surgical removal of the tumor. The results showed a marked increase in major pathologic responses among participants treated with this combination approach compared to those receiving only conventional hormone therapy.
Importantly, the study met its primary endpoints by demonstrating that the perioperative use of apalutamide substantially reduced the risk of metastasis or death in these high-risk patients. This outcome underscores the potential for apalutamide to revolutionize treatment strategies for prostate cancer, particularly in cases where the disease poses a significant threat due to its advanced stage.
These findings offer hope to many patients facing aggressive forms of prostate cancer and highlight the importance of innovative therapies that can improve long-term outcomes. The next steps will involve further analysis and validation through additional clinical trials to confirm these promising results and integrate apalutamide into standard treatment protocols.
